REFERENCES


22. Early Breast Cancer Trialists’


151. Robertson JFR. Fulvestrant (Faslodex®)—How to Make a Good Drug Better. 2007; 12: 774-84.


expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. *Gynecol Oncol* 2012; **124**: 142-7.


198. Tan DS, Rothermundt C, Thomas K, et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and


